Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
São Paulo; s.n; 2002. 129 p. ilus, tab, graf.
Thesis in Portuguese | LILACS | ID: lil-365188

ABSTRACT

A esquistossomose é a mais importante das doenças helmínticas humanas em termos de morbidez e mortalidade. A proteína Sm14 de Schistosoma mansoni, que pertence à família de proteínas ligadoras de ácidos graxos (fatty acid-binding proteins, FABPs) (Moser et al., 1991), mostrou um bom nível de proteção (65 por cento) contra a esquistossomose em animais experimentais (Tendler et al., 1996). No presente trabalho foram desenvolvidos sistemas de expressão que possibilitará a produção da proteína Sm14 em larga escala em E. coli. Com o intuito de conhecer a estrutura do gene da proteína Sm14, foi clonado um fragmento de DNA genômico de S. mansoni que contém a seqüência codificante da proteína Sm14...


Subject(s)
Animals , Mice , Escherichia coli , Fatty Acids , Genes , Methionine , Polymorphism, Genetic , Protein Isoforms , Recombinant Proteins , Schistosoma mansoni , Blotting, Western , Electrophoresis, Polyacrylamide Gel , Gene Library , Polymerase Chain Reaction/methods
2.
Mem. Inst. Oswaldo Cruz ; 96(suppl): 131-135, Sept. 2001. ilus, tab
Article in English | LILACS, SES-SP | ID: lil-295892

ABSTRACT

Previous studies carried out with Sm14 in experimental vaccination against Schistosoma mansoni or Fasciola hepatica infections were performed with recombinant Sm14 (rSm14) produced in Escherichia coli by the pGEMEX system (Promega). The rSm14 was expressed as a 40 kDa fusion protein with the major bacteriophage T7 capsid protein. Vaccination experiments with this rSm14 in animal models resulted in consistent high protective activity against S. mansoni cercariae challenge and enabled rSm14 to be included among the vaccine antigens endorsed by the World Health Organization for phase I/II clinical trials. Since the preparation of pGEMEX based rSm14 is time consuming and results in low yield for large scale production, we have tested other E. coli expression systems which would be more suitable for scale up and downstream processing. We expressed two different 6XHis-tagged Sm14 fusion proteins in a T7 promoter based plasmids. The 6XHis-tag fusions allowed rapid purification of the recombinant proteins through a Ni+2-charged resin. The resulted recombinant 18 and 16 kDa proteins were recognized by anti-Sm14 antibodies and also by antiserum against adult S. mansoni soluble secreted/excreted proteins in Western-Blot. Both proteins were also protective against S. mansoni cercariae infection to the same extent as the rSm14 expressed by the pGEMEX system


Subject(s)
Animals , Female , Mice , Schistosoma mansoni/immunology , Recombinant Proteins , Antibodies, Helminth/physiology , Helminth Proteins/physiology , Plasmids , Recombinant Proteins/isolation & purification , Carrier Proteins , Helminth Proteins/isolation & purification , Blotting, Western , Amino Acid Sequence , Vaccination , DNA, Complementary , Models, Animal , Electrophoresis, Polyacrylamide Gel , Escherichia coli , Fatty Acids
SELECTION OF CITATIONS
SEARCH DETAIL